Brain Metastases, Adult Clinical Trial
Official title:
A Phase II Trial of Surgery and Stereotactic Radiosurgery With Neoadjuvant Nivolumab and Ipilimumab in Patients With Surgically-resectable, Solid Tumor Brain Metastases
Verified date | July 2022 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases. The primary objectives of this study are to 1) assess the feasibility of neoadjuvant ipilimumab and nivolumab treatment before surgery and stereotactic radiosurgery (SRS) in patients with solid tumor brain metastases as measured by the proportion of patients who have their surgery delayed or surgery never occurs, and 2) demonstrate that neoadjuvant immunotherapy will increase proliferation of circulating T-cells compared to baseline measurements. Exploratory objectives include describing patient progression free survival and overall survival, time to local and distant intracranial progression, and the rate of radiation necrosis. The rate of radionecrosis will also be explored, as immune expression profiles.
Status | Terminated |
Enrollment | 1 |
Est. completion date | June 17, 2021 |
Est. primary completion date | June 17, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Patients must have at least 1 previously untreated, solid tumor brain metastases that are =4 cm in the largest direction. At least one of the metastases must be surgically resectable. All metastases must be planned for treatment with SRS. Primary tumor histology must be one of the following: 1. Squamous NSCLC 2. Non-squamous NSCLC without known ALK, EGFR, and ROS mutation 3. RCC 4. Urothelial carcinoma 5. Ovarian carcinoma 6. Melanoma 7. Triple negative breast cancer that is PD-L1 positive 8. Other solid tumor histologies may be eligible at the discretion of the PI if they are known to respond to immunotherapy containing regimens. - 2. Patient must be asymptomatic or minimally symptomatic, requiring the equivalent of = 4 mg dexamethasone daily for at least 7 days prior to enrollment - 3. Patient or partner(s) meets one of the following criteria: 1. Non-childbearing potential (i.e. not sexually active, physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile, or any male who has had a vasectomy). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Postmenopausal for purposes of this study is defined as 1 year without menses.; or 2. Childbearing potential and agrees to use one of the following methods of birth control: approved hormonal contraceptives (e.g. birth control pills, patches, implants, or infusions), an intrauterine device, or a barrier method of contraception (e.g. a condom or diaphragm) used with spermicide. - 4. Age = 18 years of age at the time of entry into the study - 5. Karnofsky Performance Score (KPS) = 70 - 6. Prothrombin and Partial Thromboplastin Times = 1.2 x normal prior to resection - 7. Neutrophil count = 1000 prior to resection - 8. Hemoglobin = 9 g/dl prior to resection - 9. Platelet count = 100,000/µl unsupported is necessary for eligibility on the study; however, because of risks of intracranial hemorrhage during resection, platelet count = 125,000/µl is required for the patient to undergo resection, which can be attained with the help of platelet transfusion - 10. Creatinine = 1.5 x ULN (upper limit of normal) prior to resection - 11. A signed informed consent form approved by the Institutional Review Board (IRB) will be required for patient enrollment into the study. Patients must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study - 12. Ability to undergo MRI Exclusion Criteria: - 1. Females who are pregnant or breast-feeding - 2. Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons or their designate - 3. Patients with severe, active co-morbidity, defined as follow: 1. Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (Tmax > 99.5°F/37.5°C) 2. Patients with known immunosuppressive disease or known uncontrolled human immunodeficiency virus infection 3. Patients with unstable or severe intercurrent medical conditions such as severe heart disease (New York Heart Association Class 3 or 4) - 4. Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used: - 5. Patients must not have received immunotherapy within 3 months prior to enrollment - 6. Patients with prior, unrelated malignancy requiring current active treatment in the last 3 years with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin - 7. Patients with a known history of hypersensitivity to nivolumab, or any components of nivolumab - 8. Patients with a known history of hypersensitivity to ipilimumab, or any components of ipilimumab - 9. Patients with active autoimmune disease requiring systemic immunomodulatory treatment within the past 3 months. - 10. History and/or confirmed pneumonitis, or extensive bilateral lung disease on high resolution/spiral CT scan. |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Sarah Sammons, MD | Bristol-Myers Squibb, Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Patients Who Have Their Surgery Delayed by More Than 4 Days or Surgery Never Occurs as a Direct or Indirect Result of Ipilimumab and Nivolumab Treatment. | 10 days | ||
Primary | Proliferation of Circulating T-cells as Measured by Mean Fold-change Between Baseline and Day 1 in Ki67 Levels. | Ki-67 is a nuclear protein involved in cell proliferation regulation. | baseline to day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05428852 -
Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases
|
N/A | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Recruiting |
NCT05689619 -
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
|
N/A | |
Recruiting |
NCT04197297 -
Brain Imaging Biomarkers in Patients With Brain Metastasis
|
Phase 2 | |
Recruiting |
NCT04397978 -
Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
|
||
Active, not recruiting |
NCT05095766 -
Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
|
||
Recruiting |
NCT05012254 -
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05789589 -
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT06280300 -
Multi-disciplinary Care for Brain Metastases
|
N/A | |
Recruiting |
NCT06047379 -
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
|
Phase 1/Phase 2 | |
Completed |
NCT03896555 -
Intrafractional Head Movement During Radiosurgery
|
||
Terminated |
NCT03789149 -
Focal Intraoperative Radiotherapy of Brain Metastases
|
Phase 2 | |
Recruiting |
NCT04343157 -
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
|
Phase 2 | |
Recruiting |
NCT04711824 -
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT05793489 -
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
|
N/A | |
Recruiting |
NCT04461418 -
Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT03818386 -
Radiotherapy of Multiple Brain Metastases Using AGuIX®
|
Phase 2 | |
Active, not recruiting |
NCT05087095 -
Managing Distress in Malignant Brain Cancer
|
N/A | |
Recruiting |
NCT04396717 -
Safety Study of Pritumumab in Brain Cancer
|
Phase 1 | |
Recruiting |
NCT06231186 -
a Feasibility Study of iHD-SRT for BM
|
N/A |